Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL293707 | 1.00 | AHCY (0.56) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| Trifluoroacetic Acid SCHEMBL5201752 | 1.00 | AHCY (0.56) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| Trifluoroacetic Acid SCHEMBL241441 | 0.91 | AHCY (0.48) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| Trifluoroacetic Acid SCHEMBL1412146 | 0.91 | AHCY (0.48) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL5201762 | 0.84 | ADORA3 (0.49) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL242559 | 0.84 | ADORA3 (0.49) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL5201758 | 0.84 | ADORA3 (0.49) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL242558 | 0.84 | ADORA3 (0.49) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL293708 | 0.84 | ADORA3 (0.49) | AHCYADORA3ADORA2AADORA1HSP90B1 | |
| SCHEMBL293709 | 0.84 | ADORA3 (0.49) | AHCYADORA3ADORA2AADORA1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322525-B1 | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | AHCY 4885/4885ADORA3 795/4885ADORA2A 2741/4885 |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | AHCY 1262/4885ADORA3 3/4885ADORA2A 1/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | AHCY 4885/4885ADORA3 795/4885ADORA2A 2741/4885 |
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | AHCY 4885/4885ADORA3 795/4885ADORA2A 2741/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | AHCY 4885/4885ADORA3 795/4885ADORA2A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.